课题基金 / 基金详情

Large-scale Production & Purification Of Compounds With

Large-scale Production & Purification Of Compounds With
大规模生产
批准号:
6983602
负责人:
Joseph Shiloach
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Joseph Shiloach的其他基金

相似基金

相关文献

中文摘要
翻译
生物技术股负责生物材料的生产和提纯。该股承担广泛的生物生产任务,例如大规模生长原核生物和真核生物,以及生产和提纯生物化合物,特别是蛋白质。这些产品无法从商业渠道获得,但需要用于临床和结构研究。生物技术股有能力通过实施生理和技术方法来处理这些不同的生产任务。由于该股拥有两个综合要素:一个全面运作的多用途试生产设施和进行研究和工艺开发的能力,因此有可能进行有效的工艺开发和生产。在过去的一年里,该单位进行了近200种不同的大规模准备,包括:1)培养各种微生物,如重组大肠杆菌、重组毕赤氏酵母、白喉棒状杆菌突变株、几种沙门氏菌和志贺氏菌、葡萄球菌和炭疽杆菌突变株;2)大量培养各种真核细胞,如HeLa、CHO、果蝇、SF9和HI5;3)纯化克量的白喉毒素CRM 9(交叉反应材料)、重组铜绿假单胞菌外毒素A、炭疽杆菌保护性抗原。C型葡萄球菌肠毒素,疟疾的实验性传播阻断疫苗,以及杂交瘤培养和兔血清中的几种抗体。在研究和开发领域,该单位继续以下主题的工作:1)开发更有效的大规模蛋白质回收方法,在这里,我们继续实施扩展床吸附技术以在离子交换器上捕获蛋白质,以及疏水树脂,利用新型膨胀柱该柱没有流动适配器和筛子,因此可以以较高的低速率处理更大浓度的生物量;2)进行旨在了解各种重组大肠杆菌菌株的葡萄糖代谢的研究,试图找出为什么某些菌株更适合于利用微阵列技术和蛋白质分析来生产外来蛋白质;3)通过实施厌氧生长条件,开发从大肠杆菌中表达敏感的重组梭状芽孢杆菌蛋白的发酵程序;4)进行改进毕赤酵母重组蛋白生产工艺的实验,特别是实验疟疾传播阻断疫苗;5)该单位启动了另一个与哺乳动物细胞相关的研究项目,试图了解能够在悬浮中生长的细胞和依赖锚定的细胞之间的遗传差异。此外,该股继续从HeLa/Vacinia系统生产重组蛋白的研究工作,与LDMI、NICHD合作,该股开展了针对志贺氏菌和炭疽杆菌的新疫苗的开发工作,这些产品目前正在进行现场试验。
英文摘要
The Biotechnology Unit is responsible for the production and purification of biological material. The Unit undertakes a wide array of biological production tasks such as large scale growth of prokaryotes and eucaryotes, and production and purification of biological compounds especially proteins. These products, not available from commercial sources, are needed for clinical and structural studies. The Biotechnology Unit is capable of handling these various production tasks by implementing both physiological and technical approaches. Efficient process development and production is possible since the Unit possesses two integrated elements: a fully operational multi purpose pilot production facility and the capability of conducting research and process development. During the last year the unit performed approximately 200 different, large scale preparations including: 1) growing various microorganisms such as recombinant Escherichia coli, recombinant Pichia pastoris, mutant strains of Corynebacteria diphtheria, several types of Salmonella and Shigella, Staphylococcus strains and mutant strain of Bacillus anthracis; 2) propagating large volumes of various eucaryotic cells such as HeLa, CHO, drosophila, Sf 9 and hi five; 3) purifying gram quantities of diphtheria toxin CRM 9 (Cross Reacting Material), recombinant Pseudomonas aeruginosa exotoxin A, protective antigen from Bacillus anthracis. Staphylococcal enterotoxin type C, experimental transmission blocking vaccine for malaria and several antibodies both from hybridoma culture and rabbit serum. On the research and development arena, the unit continues its work in the following topics: 1) development of more efficient methods for large scale protein recovery, here we continue our work on implementing expanded bed adsorption techniques for capturing proteins on ion exchangers, and hydrophobic resins, utilizing new types of expanded column this column does not have flow adaptors and screens and therefore can handle larger concentration of biomass at higher low rates; 2) conducting research aimed at understanding the glucose metabolism of various recombinant E. coli strains in an effort to find out why certain strains are more suitable for foreign protein production using microarrays technology and protein analysis; 3) developing fermentation procedures for expressing sensitive, recombinant clostridium protein from E.coli by implementing anaerobic growth conditions; 4) conducting experiments for improving the production protocol of recombinant proteins from Pichia pastoris, especially experiment malaria transmission blocking vaccine; 5) the unit started another research project associated with mammalian cells, trying to understand the genetic difference between cells that can grow in suspension, and cells that are anchorage dependent. In addition, the unit continues its research work on the production process of recombinant proteins from the HeLa/vaccinia system, In collaboration with LDMI, NICHD, the unit conducted work on the development of new vaccine against Shigella flexneri and Bacillus anthracis, the products are currently in field trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Large-scale production and purification of biological compounds
Production , purification and preparation of various candidiate vaccines
Identification of genes related to spcific properties of mammalian cells
Large-scale Production & Purification Of Compounds With
海外基金